dChan
Anonymous ID: c441bc May 21, 2018, 1:01 p.m. No.1496085   🗄️.is đź”—kun

BIG PHARMA CORRUPTION: LIDA

 

Localized insulin-derived amyloidosis (LIDA) is an iatrogenic disease derived from subcutaneous insulin formulations. The amyloid fibril protein is classified as amyloid insulin type, AIns, and the amyloid precursor protein is also identified as insulin.

 

The first account of LIDA in a human was in 1983. Since that time, many patient case reports have been published as well as review articles and laboratory analyses. In 1987, porcine insulin became the first foreign protein to become identified in human amyloid fibrils, a case that was discovered in a person with Type 1 diabetes where localized amyloidosis was found at the sites of insulin injection. Interestingly, this finding also established exogenous insulin as the first official case of iatrogenic amyloidosis.

 

  • Discovered in 50 people between January 2010 and May 2013—hardly suggestive of being an uncommon or rare occurrence.*

 

Remarkably, the exact pathogenesis of LIDA remains unclear.

 

Subcutaneous insulin formulations have historically been known for their poor stability. Rapid acting analogs, a form of subcutaneous insulin, have modified insulin's amino acid sequences to prevent the self assembly of insulin into hexamers and to favorably promote dissociation into monomers. Numerous additives are also included in subcutaneous insulin formulations, some of them known to be toxic: m-cresol and phenol, which could potentially in facilitating aggregation and/or denaturation of the insulin in the formulation.

 

  • Currently, this adverse reaction is not disclosed on insulin labels or by the FDA or ADA, despite it being a known complication since the 1980's. *

 

LIDA has yet to be disclosed of to the medical community.

 

When considering the dearth of information on LIDA compared to the quantity of occurrences, the plausibility of LIDA being an uncommon or rare occurrence is highly unlikely.

 

Treatment for LIDA is surgical excision of the amyloid mass.

 

However, recent findings in a patient with diabetes who developed LIDA has revealed that the amyloid mass is capable of continued growth despite complete avoidance of insulin injections at the site of the mass.

 

There is zero mention of LIDA on subcutaneous insulin labels, FDA website, ADA nor the Standards of Care. Awareness has been suppressed, attention manipulated and diverted to avoid disclosure of dangerous localized insulin-derived amyloidosis required by US law.

 

Evidence:

 

  1. Localized Amyloidosis at the Site of Repeated Insulin Injection in a Diabetic Patient

 

www.jstage.jst.go.jp/article/internalmedicine/49/5/49_5_397/_pdf

 

  1. Progressive insulin-derived amyloidosis in a patient with type 2 diabetes

 

www.ncbi.nlm.nih.gov/pmc/articles/PMC5095519/

 

  1. Insulin-derived Amyloidosis and Poor Glycemic Control: A Case Series

 

www.amjmed.com/article/S0002-9343(14)00035-7/fulltext

 

  1. Localized insulin-derived amyloidosis: A potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate

 

onlinelibrary.wiley.com/doi/10.1002/ajh.23334/full

 

  1. Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report

 

www.humanpathol.com/article/S0046-8177(09)00167-1/abstract

 

  1. Cutaneous amyloidosis at the site of insulin injection with coexistence of acanthosis nigricans

 

www.ijpmonline.org/article.asp?issn=0377-4929;year=2014;volume=57;issue=1;spage=127;epage=129;aulast=Nandeesh

 

  1. Insulin Derived Amyloidosis

 

www.ncbi.nlm.nih.gov/pmc/articles/PMC4287767/

 

  1. Ultrasonography Improves Glycemic Control by Detecting Insulin-Derived Localized Amyloidosis

 

www.umbjournal.org/article/S0301-5629(17)30279-X/pdf

 

  1. A Case of Insulin Resistance Secondary to Insulin Induced Localized Cutaneous Amyloidosis.

 

www.bloodjournal.org/content/114/22/4908?sso-checked=true

 

  1. Amyloidoma secondary to insulin injection: Cytologic diagnosis and pitfalls

 

www.ncbi.nlm.nih.gov/pmc/articles/PMC4527044/

 

  1. Localized insulin amyloidosis with use of a concentrated insulin: a potential complication

 

onlinelibrary.wiley.com/doi/10.1111/dme.13137/abstract